5th Feb 2015 07:15
LONDON (Alliance News) - AstraZeneca PLC Thursday moved to further bolster its respiratory drug pipeline by acquiring the rights to Actavis' branded respiratory business in the US and Canada, as it reported lower earnings for 2014 due to increased investments it is making in accelerating its existing portfolio.
The news came as medical devices company Smith & Nephew PLC reported higher 2014 earnings, buoyed by a sustained improvement in US reconstruction markets and higher growth in emerging markets, and GlaxoSmithKline sold its entire stake in Gemab AS.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaSmith & NephewGlaxosmithkline